Rhumbline Advisers Buys 8,619 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Rhumbline Advisers grew its holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 17.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 56,874 shares of the company’s stock after purchasing an additional 8,619 shares during the quarter. Rhumbline Advisers’ holdings in Zevra Therapeutics were worth $279,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Price T Rowe Associates Inc. MD bought a new position in shares of Zevra Therapeutics in the 1st quarter valued at about $64,000. Focus Financial Network Inc. ADV bought a new position in shares of Zevra Therapeutics in the 4th quarter valued at about $141,000. Virtu Financial LLC bought a new position in shares of Zevra Therapeutics in the 4th quarter valued at about $177,000. Jacobs Levy Equity Management Inc. boosted its stake in shares of Zevra Therapeutics by 102.4% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company’s stock valued at $201,000 after purchasing an additional 17,557 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of Zevra Therapeutics by 10.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 220,499 shares of the company’s stock valued at $1,080,000 after purchasing an additional 21,231 shares during the last quarter. Institutional investors own 35.03% of the company’s stock.

Analyst Ratings Changes

ZVRA has been the topic of a number of analyst reports. Maxim Group increased their price target on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a research report on Tuesday. Roth Mkm increased their price target on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a research report on Tuesday. JMP Securities initiated coverage on shares of Zevra Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $17.00 price target on the stock. Canaccord Genuity Group cut their price target on shares of Zevra Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a research report on Wednesday, September 18th. Finally, HC Wainwright increased their price target on shares of Zevra Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Friday, September 20th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $21.00.

Insider Transactions at Zevra Therapeutics

In other Zevra Therapeutics news, Director John B. Bode purchased 10,000 shares of the firm’s stock in a transaction dated Friday, July 12th. The stock was bought at an average cost of $5.87 per share, with a total value of $58,700.00. Following the purchase, the director now directly owns 30,000 shares of the company’s stock, valued at $176,100. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Insiders acquired 22,000 shares of company stock valued at $140,340 in the last ninety days. 2.40% of the stock is currently owned by corporate insiders.

Zevra Therapeutics Stock Performance

Shares of ZVRA stock opened at $6.92 on Friday. The company has a debt-to-equity ratio of 1.80, a quick ratio of 2.00 and a current ratio of 2.00. The company has a market capitalization of $364.13 million, a P/E ratio of -5.13 and a beta of 1.94. The company’s 50 day moving average price is $7.16 and its two-hundred day moving average price is $5.76. Zevra Therapeutics, Inc. has a 52 week low of $3.89 and a 52 week high of $8.95.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.01). The business had revenue of $4.45 million for the quarter, compared to the consensus estimate of $4.08 million. Zevra Therapeutics had a negative return on equity of 124.85% and a negative net margin of 274.10%. During the same period in the prior year, the business earned ($0.15) earnings per share. On average, analysts expect that Zevra Therapeutics, Inc. will post -1.59 earnings per share for the current fiscal year.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.